TLSA (Tiziana Life Sciences) PS Ratio: (As of Jun. 28, 2026)


TLSA Tiziana Life Sciences Ltd TLSA
30 GF Score
Price $1.20
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tiziana Life Sciences's share price is $1.195. Tiziana Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Hence, Tiziana Life Sciences's PS Ratio for today is .

The historical rank and industry rank for Tiziana Life Sciences's PS Ratio or its related term are showing as below:

TLSA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.155
* Ranked among companies with meaningful PS Ratio only.

Tiziana Life Sciences's Revenue per Sharefor the six months ended in Dec. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.

Back to Basics: PS Ratio


Tiziana Life Sciences  (NAS:TLSA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Tiziana Life Sciences PS Ratio Related Terms


Tiziana Life Sciences PS Ratio Historical Data

* Premium members only.

The historical data trend for Tiziana Life Sciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tiziana Life Sciences PS Ratio Chart

Tiziana Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tiziana Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TLSA vs DTIL, MIST, EQ: PS Ratio Comparison

For the Biotechnology subindustry, Tiziana Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tiziana Life Sciences PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's PS Ratio falls into.


TLSA
30GF Score
Tiziana Life Sciences Ltd TLSA
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Tiziana Life Sciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.195/0
=

Tiziana Life Sciences's Share Price of today is $1.195.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tiziana Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Tiziana Life Sciences Business Description

Other Exchanges 0RP:Germany
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score

Get the complete analysis for TLSA

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.20
Price